The essentials
Approved daraxonrasib costs $39,800 monthly; 2,000+ patients already accessed it.
With daraxonrasib now FDA-approved, pricing has been set at $39,800 for a 30-day supply, raising questions about medication accessibility for pancreatic cancer patients. The cost reflects the drug's advanced manufacturing and development, though affordability remains a barrier for many patients without comprehensive insurance coverage.
Access has already begun through an expanded-access program that has provided daraxonrasib to over 2,000 patients prior to formal approval. This initiative allowed patients to receive treatment while clinical trials were ongoing, demonstrating both the urgency of the medical need and the logistical complexity of distributing a newly approved drug. The gap between the price point and patient access will likely shape how widely this precision cancer therapy reaches eligible populations.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Expanded program reaches thousands before formal launch
Over 2,000 patients accessed daraxonrasib through expanded access, demonstrating the drug's availability pathway before standard approval. This pre-approval access provided critical treatment to patients while regulatory processes completed, showing how manufacturers can bridge the gap between development and market availability.
Monthly price of $39,800 raises affordability concerns
Rasonque is priced at $39,800 for a 30-day supply, positioning it as a high-cost therapy. This pricing structure may limit access for uninsured or underinsured patients, despite the drug's clinical effectiveness in treating KRAS-mutant pancreatic cancer.